B-cell and T-cell lymphomas are both cancers of the immune system’s white blood cells, but they differ in almost every way that matters to a patient: which cell goes rogue, how common it is, how it behaves in the body, how doctors identify it, and what treatments work against it. Roughly 85 to 90 percent of non-Hodgkin lymphomas arise from B cells, making T-cell lymphomas a comparatively rare and often more challenging diagnosis. Understanding the split between them is not just an academic exercise; it shapes the drugs you receive, the monitoring you undergo, and, in many cases, your outlook.
The Cells They Come From
B cells and T cells are the two main branches of the adaptive immune system, and they have very different jobs. B cells are the body’s antibody factories. Research going back to the 1960s and 1970s established that B lymphocytes are primarily responsible for producing protective antibodies, the proteins that tag invaders for destruction.1PubMed Central. B lymphocytes: how they develop and function T cells, meanwhile, develop in the thymus gland and orchestrate more direct forms of immune defense. The thymus guides T cells through a careful maturation process that weeds out cells likely to attack the body’s own tissues, then exports the survivors into the bloodstream to recognize and fight pathogens.2PubMed Central. The Role of the Thymus in the Immune Response
When either cell type acquires enough genetic damage to grow uncontrollably, the result is lymphoma. But because B cells and T cells have different surface proteins, internal signaling pathways, and life cycles, the cancers they produce look and act quite differently under the microscope and in the clinic.
How Common Is Each Type
The imbalance is striking. Among all non-Hodgkin lymphomas, B-cell subtypes account for about 85 to 90 percent of cases.3PubMed Central. B-cell Non-Hodgkin lymphomas That leaves T-cell and natural killer (NK) cell lymphomas making up the remaining fraction. This rarity has real consequences: fewer patients means fewer large clinical trials, which means doctors sometimes have less certainty about the best treatment approach for T-cell disease. It also means that a community oncologist may see a T-cell lymphoma only a handful of times in a career, whereas B-cell subtypes like diffuse large B-cell lymphoma (DLBCL) are among the most common cancers period.
Geography and ethnicity influence the balance somewhat. Certain T-cell and NK-cell lymphomas are more prevalent in East Asia and parts of Central and South America, often in connection with specific viral infections. Within the B-cell category, even specific subtypes show geographic variation; mantle cell lymphoma, for instance, has measurable differences in incidence across different regions of the United States alone.4Blood. Trend and Geographic Variations in the Incidence of Mantle Cell Lymphoma in the United States over 30 Years from 1975 to 2004
Viruses That Push Each Cell Toward Cancer
Viruses cause roughly 12 percent of all human cancers, and lymphoma is one of the places where that link is especially visible.5PubMed Central. Viral-driven oncogenesis in T/NK-cell lymphomas: parallels and divergences between HTLV-1 and EBV The two viruses that matter most here are Epstein-Barr virus (EBV) and human T-cell leukemia virus type 1 (HTLV-1), and each has a somewhat different relationship with the two cell types.
EBV is best known for its tropism toward B cells. It attaches to a surface molecule called CD21 on B cells, slips inside, and flips on a suite of genes that drive the cell into a kind of immortalized resting state. The infected B cell looks calm but is primed for future cancerous changes.6PubMed Central. Diffuse Large B-Cell Lymphoma in Human T-Lymphotropic Virus Type 1 Carriers EBV can also drive certain T-cell and NK-cell cancers. Extranodal NK/T-cell lymphoma, nasal type, is a rare and aggressive disease strongly associated with EBV, most often appearing in middle-aged men and typically arising in the nasal cavities or surrounding structures.7Journal of Clinical Review & Case Reports. Extranodal nk/t-cell lymphoma, nasal type: a clinical cases presentation and review of literature
HTLV-1 takes a different route. It is a retrovirus that infects many cell types but is most notorious for causing adult T-cell leukemia-lymphoma (ATL). A viral protein called Tax revs up the cell cycle in infected cells, making them vulnerable to accumulating genetic damage over decades.6PubMed Central. Diffuse Large B-Cell Lymphoma in Human T-Lymphotropic Virus Type 1 Carriers That long latency period explains why ATL typically appears in midlife or later, well after the initial infection. Viral genes like Tax and another factor called HBZ help infected cells evade the immune system and hijack normal signaling pathways, eventually leading to uncontrolled growth.5PubMed Central. Viral-driven oncogenesis in T/NK-cell lymphomas: parallels and divergences between HTLV-1 and EBV
Molecular and Genetic Differences
The mutations and gene rearrangements that drive B-cell and T-cell lymphomas are largely distinct, reflecting the different biology of the two cell lineages.
In B-cell lymphomas, some of the most consequential abnormalities involve rearrangements of the MYC, BCL2, and BCL6 genes. Cancers carrying simultaneous rearrangements in MYC and BCL2 are called “double-hit” lymphomas, and those with all three are “triple-hit” lymphomas. These are rare but aggressive; the WHO classification system now groups them under the category of high-grade B-cell lymphoma.8Blood. Transformation of Follicular Lymphoma to a High Grade B-Cell Lymphoma with MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia 9PubMed. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases Another key player on the B-cell side is EZH2, an enzyme that normally helps regulate gene expression by modifying proteins called histones. When EZH2 is overactive or mutated, it can silence tumor-suppressor genes and push cells toward malignancy.10PubMed Central. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations
T-cell lymphomas tend to harbor a different set of genetic problems, many centered on the T-cell receptor (TCR) signaling pathway. One of the most common mutations involves RHOA, found in about 60 percent of cases in one study of follicular helper T-cell-derived lymphomas. Other frequently mutated genes in these cancers include PLCG1, CD28, and components of the PI3K pathway. The vast majority of these variants are gain-of-function, meaning they make the signaling pathway more active than it should be, pushing the cell to proliferate.11PubMed. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas 12PubMed Central. Mutations Affecting Genes in the Proximal T-Cell Receptor Signaling Pathway in Peripheral T-Cell Lymphoma
How Doctors Tell Them Apart
Distinguishing B-cell from T-cell lymphoma starts with a tissue biopsy, but the real workhorse of classification is a technique called flow cytometry. This technology labels cells with fluorescent markers that bind to specific surface proteins, then runs the cells through a laser one by one. Because B cells and T cells carry different surface markers, flow cytometry can quickly sort out which lineage a cancer belongs to. For B-cell lymphomas, characteristic markers like CD19 and CD20 are looked for, while T-cell lymphomas express markers like CD3, CD4, or CD8.13PubMed Central. Flow Cytometry for B-Cell Non-Hodgkin and Hodgkin Lymphomas
Classification does not stop at “B” or “T.” Within each lineage there are dozens of recognized subtypes, and identifying the right one matters for treatment. Peripheral T-cell lymphomas, in particular, are famously heterogeneous. Many cases resist easy classification and end up in a catch-all category called “peripheral T-cell lymphoma, not otherwise specified” (PTCL-NOS). Gene expression profiling has split that group further into subtypes with meaningfully different outcomes.14Modern Pathology. Comprehensive pathologic and molecular characterization of peripheral T-cell lymphoma subtypes 15PubMed Central. Genetic Landscape and Classification of Peripheral T Cell Lymphomas The challenge of T-cell lymphoma classification is one reason a diagnosis sometimes takes longer or requires a second opinion at a specialized center.
Treatment Diverges Sharply
Here is where the B-cell versus T-cell distinction has the most practical impact on a patient’s life.
Rituximab and B-Cell Targeting
The treatment of B-cell lymphomas was transformed by rituximab, a monoclonal antibody that targets CD20 on the surface of B cells. It was the first antibody approved by the FDA for cancer treatment and remains a backbone of therapy across many B-cell lymphoma subtypes.16PubMed. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy Rituximab works through several mechanisms at once: it recruits the immune system’s complement proteins to punch holes in the cancer cell, it flags cancer cells for destruction by natural killer cells, and it can trigger the cancer cell to self-destruct.17PubMed Central. Rituximab: mechanism of action Combined with standard chemotherapy (a regimen commonly called R-CHOP), rituximab dramatically improved survival for patients with DLBCL and many other B-cell lymphomas.
T-cell lymphomas do not express CD20, so rituximab is useless against them. This is one of the sharpest practical dividing lines between the two disease families. For years, T-cell lymphoma patients received the same chemotherapy backbones as B-cell patients but without the added benefit of a targeted antibody, contributing to generally worse outcomes.
Drugs That Work on T-Cell Lymphomas
The targeted therapy landscape for T-cell lymphomas has been catching up, though it remains less mature. Histone deacetylase inhibitors (HDAC inhibitors) have emerged as an especially promising class. Drugs like romidepsin, belinostat, and chidamide work by blocking enzymes that modify how DNA is packaged, which in turn flips gene expression in a way that can halt cancer cell growth and trigger cell death.18PubMed Central. Histone Deacetylase Inhibitors for Peripheral T-Cell Lymphomas Several of these have shown durable responses in patients with peripheral T-cell lymphomas, either alone or combined with conventional chemotherapy.19PubMed Central. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
Another drug that bridges the gap somewhat is brentuximab vedotin, an antibody-drug conjugate that targets CD30, a protein expressed on some B-cell and T-cell lymphomas. In clinical trials, responses to brentuximab vedotin were observed across a range of CD30 expression levels. Among patients with peripheral T-cell lymphoma and CD30 expression of 10 percent or higher, the overall response rate was about 45 percent, and even patients with lower or undetectable CD30 showed some responses, though the numbers were small.20The Oncologist. Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma Brentuximab vedotin has become a standard part of treatment for certain T-cell subtypes, particularly anaplastic large cell lymphoma.
CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has been a genuine breakthrough for B-cell lymphomas. In this approach, a patient’s own T cells are removed, genetically engineered to recognize a surface protein on the cancer (usually CD19), and infused back into the body. Three CAR T-cell products targeting CD19 have been FDA-approved for relapsed or refractory aggressive B-cell lymphoma, and approvals have expanded to mantle cell lymphoma and follicular lymphoma as well.21PubMed Central. CAR T-cell therapy for B-cell lymphoma For patients who have failed multiple lines of treatment, CAR T-cell therapy can produce durable remissions that were previously unheard of.
CAR T-cell therapy for T-cell lymphomas is a much harder engineering problem. Because the engineered cells and the cancer cells are both T cells, they share many of the same surface markers. Engineering a CAR T cell to kill anything with a T-cell marker risks having it destroy the therapeutic cells themselves, a problem sometimes called fratricide. Research is active, but as of now, there are no FDA-approved CAR T-cell products for T-cell lymphoma. This is one of the starkest examples of how the B-cell versus T-cell distinction translates into unequal access to cutting-edge treatment.
The Immune System During and After Treatment
Both types of lymphoma disrupt normal immune function, but in somewhat different ways. B-cell lymphomas and related diseases are accompanied by a broad range of immune problems, from autoimmune symptoms and hyperinflammation to straightforward immune deficiency and increased vulnerability to infections.22PubMed Central. Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy The specific pattern depends on which immune pathway the cancer disrupts most. Treatments that target B cells, like rituximab or CAR T-cell therapy, wipe out both cancerous and healthy B cells, leading to low antibody levels that can persist for months or longer after treatment ends. Patients may need immunoglobulin infusions to fill that gap.
The tumor microenvironment, meaning the ecosystem of immune and support cells surrounding the cancer, also differs between the two lineages. In B-cell lymphomas, the cancer cells actively recruit and reshape surrounding immune cells to support their survival. That microenvironment can range from intensely inflammatory to deeply suppressed depending on the subtype.23PubMed Central. Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application Hodgkin lymphoma, where the malignant cells are B-cell derived but scarce, sits at the inflammatory extreme, while chronic lymphocytic leukemia tends toward immune suppression. T-cell lymphomas have their own microenvironment dynamics, but the field’s understanding is less advanced, again a consequence of the rarity of these cancers and fewer large studies to draw on.
Pediatric Lymphoma Looks Different
In children and adolescents, the landscape shifts. T-cell lymphomas make up a larger share of pediatric non-Hodgkin lymphoma than they do in adults. The three most common pediatric T-cell subtypes are T-lymphoblastic lymphoma, anaplastic large cell lymphoma, and PTCL-NOS. Despite their rarity in absolute numbers, molecular discoveries in these diseases have been exciting, improving both diagnostic accuracy and the ability to use targeted therapies.24PubMed Central. Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies Anaplastic large cell lymphoma in children, for example, often carries a specific gene fusion involving a kinase called ALK, and ALK-positive cases tend to respond well to treatment, giving those patients a more favorable prognosis than many adult T-cell lymphoma patients experience.
Liquid Biopsy and the Future of Monitoring
One area where B-cell and T-cell lymphomas are converging is in the use of liquid biopsy, a technology that detects fragments of tumor DNA circulating in the blood (called circulating tumor DNA, or ctDNA). For DLBCL, studies have found a molecular marker in the ctDNA of about 90 percent of patients at diagnosis. Tracking how quickly those levels drop during treatment adds real prognostic power: in one study, patients who achieved a major molecular response after two cycles of chemotherapy had a two-year progression-free survival of 76 percent, compared with 0 percent in those who did not.25PubMed. Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease
Liquid biopsy is proving useful in T-cell lymphomas too. In aggressive T-cell subtypes, ctDNA levels align with tumor burden and show high agreement with what traditional tissue biopsies reveal.26PubMed Central. Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside This matters because T-cell lymphomas sometimes arise in locations that are hard to biopsy repeatedly, such as deep in the abdomen or in the skin. A blood draw that tracks the cancer’s genetic fingerprint could spare patients from additional invasive procedures and give oncologists real-time feedback on whether treatment is working.
How Classification Has Evolved
If the number of lymphoma subtypes feels overwhelming, there is a reason. Lymphoma classification has been one of the most contentious areas in pathology for over a century, progressing from crude microscopic descriptions to today’s detailed molecular portraits. The modern era began in the 1970s when researchers first proposed dividing lymphomas by whether they originated from B cells or T cells, an approach that was controversial at the time.27PubMed. As the world turns, evolving lymphoma classifications-past, present and future A strictly appearance-based system dominated the 1980s before a rational, biology-first approach returned in the 1990s and eventually became the foundation of the WHO classification system. The current WHO 5th Edition uses a combination of cell lineage, molecular findings, and clinical behavior to define dozens of specific entities.28PubMed Central. Hodgkin Lymphoma Classification-From Historical Concepts to Current Refinements
For patients, the practical takeaway is that a lymphoma diagnosis today should come with a specific subtype name, not just “B-cell lymphoma” or “T-cell lymphoma.” That name determines the treatment plan, the expected course of disease, and eligibility for clinical trials. If your pathology report is vague, asking your oncologist to clarify the exact subtype is one of the most useful questions you can pose.